S&P 500   4,212.84 (+0.79%)
DOW   33,091.43 (+0.56%)
QQQ   350.00 (+0.58%)
AAPL   179.33 (+1.17%)
MSFT   329.60 (+0.37%)
META   268.76 (+1.53%)
GOOGL   122.93 (+0.05%)
AMZN   121.84 (+1.04%)
TSLA   203.70 (-0.11%)
NVDA   392.71 (+3.80%)
NIO   7.53 (+0.00%)
BABA   83.15 (+4.53%)
AMD   119.37 (+0.98%)
T   15.87 (+0.89%)
F   12.07 (+0.58%)
MU   68.95 (+1.10%)
CGC   0.85 (+2.35%)
GE   104.55 (+2.97%)
DIS   88.45 (+0.56%)
AMC   4.64 (+3.11%)
PFE   38.16 (+0.37%)
PYPL   62.91 (+1.48%)
NFLX   400.79 (+1.41%)
S&P 500   4,212.84 (+0.79%)
DOW   33,091.43 (+0.56%)
QQQ   350.00 (+0.58%)
AAPL   179.33 (+1.17%)
MSFT   329.60 (+0.37%)
META   268.76 (+1.53%)
GOOGL   122.93 (+0.05%)
AMZN   121.84 (+1.04%)
TSLA   203.70 (-0.11%)
NVDA   392.71 (+3.80%)
NIO   7.53 (+0.00%)
BABA   83.15 (+4.53%)
AMD   119.37 (+0.98%)
T   15.87 (+0.89%)
F   12.07 (+0.58%)
MU   68.95 (+1.10%)
CGC   0.85 (+2.35%)
GE   104.55 (+2.97%)
DIS   88.45 (+0.56%)
AMC   4.64 (+3.11%)
PFE   38.16 (+0.37%)
PYPL   62.91 (+1.48%)
NFLX   400.79 (+1.41%)
S&P 500   4,212.84 (+0.79%)
DOW   33,091.43 (+0.56%)
QQQ   350.00 (+0.58%)
AAPL   179.33 (+1.17%)
MSFT   329.60 (+0.37%)
META   268.76 (+1.53%)
GOOGL   122.93 (+0.05%)
AMZN   121.84 (+1.04%)
TSLA   203.70 (-0.11%)
NVDA   392.71 (+3.80%)
NIO   7.53 (+0.00%)
BABA   83.15 (+4.53%)
AMD   119.37 (+0.98%)
T   15.87 (+0.89%)
F   12.07 (+0.58%)
MU   68.95 (+1.10%)
CGC   0.85 (+2.35%)
GE   104.55 (+2.97%)
DIS   88.45 (+0.56%)
AMC   4.64 (+3.11%)
PFE   38.16 (+0.37%)
PYPL   62.91 (+1.48%)
NFLX   400.79 (+1.41%)
S&P 500   4,212.84 (+0.79%)
DOW   33,091.43 (+0.56%)
QQQ   350.00 (+0.58%)
AAPL   179.33 (+1.17%)
MSFT   329.60 (+0.37%)
META   268.76 (+1.53%)
GOOGL   122.93 (+0.05%)
AMZN   121.84 (+1.04%)
TSLA   203.70 (-0.11%)
NVDA   392.71 (+3.80%)
NIO   7.53 (+0.00%)
BABA   83.15 (+4.53%)
AMD   119.37 (+0.98%)
T   15.87 (+0.89%)
F   12.07 (+0.58%)
MU   68.95 (+1.10%)
CGC   0.85 (+2.35%)
GE   104.55 (+2.97%)
DIS   88.45 (+0.56%)
AMC   4.64 (+3.11%)
PFE   38.16 (+0.37%)
PYPL   62.91 (+1.48%)
NFLX   400.79 (+1.41%)
NASDAQ:ONVO

Organovo (ONVO) Stock Forecast, Price & News

$1.72
+0.02 (+1.18%)
(As of 11:36 AM ET)
Compare
Today's Range
$1.70
$1.74
50-Day Range
$1.70
$2.27
52-Week Range
$1.37
$3.72
Volume
19,980 shs
Average Volume
81,579 shs
Market Capitalization
$14.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ONVO stock logo

About Organovo (NASDAQ:ONVO) Stock

Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.

Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

ONVO Stock News Headlines

StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Organovo (NASDAQ:ONVO) Now Covered by StockNews.com
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Organovo Announces FXR Program
Organovo Holdings, Inc. (ONVO)
See More Headlines

ONVO Price History

ONVO Company Calendar

Last Earnings
8/08/2019
Today
6/01/2023
Next Earnings (Estimated)
6/09/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONVO
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-11,450,000.00
Pretax Margin
-685.54%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$3.47 per share

Miscellaneous

Free Float
8,366,000
Market Cap
$14.81 million
Optionable
Optionable
Beta
0.89

Key Executives

  • Keith Murphy
    Executive Chairman & Chief Executive Officer
  • Thomas P. Hess
    Chief Financial & Accounting Officer
  • Jeffrey N. Miner
    Chief Scientific Officer
  • Curtis Tyree
    Senior VP-Strategy & Business Development
  • Steve E. Kunszabo
    VP-Investor Relations & Corporate Communications













ONVO Stock - Frequently Asked Questions

How have ONVO shares performed in 2023?

Organovo's stock was trading at $1.41 on January 1st, 2023. Since then, ONVO shares have increased by 20.6% and is now trading at $1.70.
View the best growth stocks for 2023 here
.

When is Organovo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, June 9th 2023.
View our ONVO earnings forecast
.

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) posted its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($1.00) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($1.00). The medical research company had revenue of $0.67 million for the quarter, compared to analysts' expectations of $0.77 million.

When did Organovo's stock split?

Shares of Organovo reverse split before market open on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Taylor Crouch's approval rating as Organovo's CEO?

3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Who are Organovo's major shareholders?

Organovo's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.51%) and Susquehanna International Group LLP (0.70%).
View institutional ownership trends
.

How do I buy shares of Organovo?

Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $1.70.

How much money does Organovo make?

Organovo (NASDAQ:ONVO) has a market capitalization of $14.81 million and generates $1.50 million in revenue each year. The medical research company earns $-11,450,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

How can I contact Organovo?

Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The official website for the company is www.organovo.com. The medical research company can be reached via phone at (858) 224-1000 or via email at ir@organovo.com.

This page (NASDAQ:ONVO) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -